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Abstract 
 
Aims: To retrospectively evaluate the potential impact of statin and aspirin use on 
acute toxicity and pathological complete response rate (pCR) in rectal cancer 
patients receiving neo-adjuvant long course radiation (LCRT) with concurrent 
chemotherapy. 
 
Methods: A retrospective review was performed of all patients undergoing neo-
adjuvant LCRT for rectal adenocarcinoma at the Regional Cancer Treatment Service 
between 1 September 2007 and 1 June 2011.  Data obtained include demographic 
details; date and radiological TNM stage at diagnosis; medication taken at time of 
radiation therapy; toxicity during LCRT; and surgical histology to determine if a pCR 
was obtained following LCRT. 
 
Results: Neo-adjuvant LCRT was administered to 142 patients for rectal cancer 
during this period; concurrent chemotherapy was omitted in 13 due to significant co-
morbidities.  TNM stage was 2 or 3 radiologically at diagnosis in 127 (89.4%) of 
patients. At the time of LCRT 23% were taking a statin and 25% were taking aspirin.  
Of 135 assessable patients, 34 (13%) achieved a pCR at surgery. On logistic 
regression pCR was not significantly associated with the use of chemotherapy, 
statins, aspirin, other NSAIDs, T-stage or N-stage. There was no significant 
correlation between statin or aspirin use with bladder or rectal toxicity.  Actuarial 
time to maximum rectal toxicity was not different in statin users or non-users. 
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Conclusion: In contrast to other larger retrospective series, this study did not find 
improvements in toxicity or pCR rate through statin or aspirin use in rectal cancer 
patients undergoing LCRT. Their potential benefits in this setting would be best 
studied prospectively in a large randomised trial. 
 
Keywords: chemo-radiation; rectal cancer; statin; aspirin 
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Introduction 
While advances in the management of rectal cancer have reduced local relapse to 
less than 10% in most patients, those with TNM tumour stage T4 and higher-risk T3 
node-positive tumours still have higher local relapse rates. In addition, distant 
relapse still occurs in 25-30%, with a similar proportion dying within 5 years (1).  
Statins are a class of drugs that inhibit the mevalonate pathway through inhibition of 
the rate-controlling enzyme, 3-hydroxy-3-methyl-glutaryl-CoA reductase. While they 
are commonly used to lower cholesterol, it appears that modulation of this signalling 
pathway may also improve cancer outcomes (2). A Danish population study of 
295,925 cancer cases diagnosed between 1995 and 2007 revealed that the use of 
statins significantly improved overall survival (OS) in the whole cohort, and 
specifically within the colorectal cancer (CRC) group (HR 0.79, 95% CI 0.74–0.85) (3). 
Similarly a registry study of 17,115 CRC patients from Taiwan reported that 
multivariate cancer-specific mortality was significantly reduced in statin users (HR 
0.77, p < 0.001)(4). More recently a population-based cohort study of 7657 patients 
with CRC in the United Kingdom showed that statin use improved CSS (fully adjusted 
HR, 0.71; 95% CI, 0.61 to 0.84) and all-cause mortality (fully adjusted HR, 0.75; 95% 
CI, 0.66 to 0.84) (5). 
 
Preclinical studies have elaborated mechanisms that may contribute to improved 
cancer outcomes with statins, many of which relate to effects on cell signalling that 
are independent of cholesterol metabolism (6). These include mechanisms that can 
improve treatment efficacy as well as inhibition of radiation (RT)-induced gut and 
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skin toxicities (7-14). Thus there appears to be a specific and beneficial interaction of 
statins with RT.  
 
This correlates with retrospective clinical studies in which patients taking statins 
during chemo-RT for rectal cancer at Memorial Sloan-Kettering Cancer Center 
(n=349), Cleveland Clinic (n=407) or 5 Canadian hospitals (n=891) had significantly 
higher rates of pathological complete response (pCR) on multivariate analysis, 
ranging from 1.7 to 4.5 (15-17). In contrast no benefit from statin use was seen in a 
large trial (n=842) of adjuvant chemotherapy for colon cancer (18). Furthermore, a 
prospective observational study of 308 patients at the Royal Marsden Hospital, 
London, treated with radical pelvic RT reported that those taking statins had 
significantly reduced RT-induced bowel toxicity, both during treatment (p=0.04) and 
one year later (19). 
 
Aspirin’s inhibition of platelet activation, platelet-tumour cell adhesion, angiogenesis 
and metastasis, as well as therapeutic interactions with chemotherapy and RT, have 
demonstrated survival benefits in CRC patients in some series (20-23) though not all 
(24).  Interestingly, even though statins and aspirin may both improve outcomes 
through inhibiting inflammation, the benefit of statins is still seen when controlling 
for aspirin use (4)    
 
We retrospectively explored the potential benefit of using statin and/or aspirin or 
other non-steroidal anti-inflammatory drugs (NSAIDs) in the clinical setting of rectal 
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cancer patients receiving a standard course of neo-adjuvant long-course radiation 
therapy (LCRT) with concurrent chemotherapy (chemo-RT).  We report the 
association of the use of statins and NSAIDS in this patient group with the acute 
toxicity of their treatment and the pCR rate found at the time of surgery. 
 
Methods 
The electronic oncology notes were reviewed of all patients diagnosed with rectal 
cancer between 1
st
 September 2007 and 1
st
 June 2011 who underwent LCRT for 
rectal cancer at the Regional Cancer Treatment Service (RCTS), Palmerston North 
Hospital.  Hospital paper notes were reviewed when the electronic record was 
incomplete.  Data was obtained regarding patient’s demographic details; date and 
radiological TNM stage at diagnosis; medication taken at time of radiation therapy; 
toxicity during LCRT; and surgical histology to determine if a pCR was obtained 
following LCRT.  While the names of any statins and NSAIDs used during treatment 
was recorded, due to the retrospective nature of this study the details on dosage, 
duration of use and indication for these drugs were not available to the 
investigators.  
 
The electronic oncology notes prospectively recorded weekly toxicity evaluation 
(graded according to the Common Toxicity Criteria Version 3.0 (25)) during LCRT, 
hospital admissions or if treatment was stopped early due to toxicity.  For the 
purposes of this study, the most severe bowel and bladder toxicity that developed 
during radiation treatment was documented.  
 
Page 6 of 24
Asia Pacific Journal of Clinical Oncology
Asia Pacific Journal of Clinical Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
LCRT was offered to all patients who were node-positive on MRI staging of their 
rectal cancer and/or had a threatened circumferential resection margin. LCRT was 
also considered if the surgeon felt resection would be difficult due to tumour bulk.  
LCRT was delivered as a 3D conformal technique using 15MV photons in 2 phases: 
phase 1 delivered a dose of 45 Gray (Gy) in 25 fractions over 5 weeks to the pelvis; 
phase 2 delivered a boost dose to the rectal tumour of 5.4 Gy in 3 fractions over 3 
days.  Concurrent chemotherapy (capecitabine 825 mg/m
2
 twice daily or continuous 
IV infusion of 5-fluorouracil [5FU] 225 mg/m
2
/day) was administered with LCRT as 
standard practice, unless medical fitness or co-morbidities precluded this (in some of 
these patients bolus 5FU was given at a dose of 500mg/m
2
 on days 1 – 5 of week 1 
and week 5 of radiation treatment).  On completion of LCRT, definitive surgery 
(either total mesorectal excision or abdomino-perineal resection) took place 6 – 8 
weeks later. 
 
Statistical analysis of this dataset was undertaken using Spearman correlation 
between patient, tumour and treatment parameters and toxicity and pCR rate.  
Logistic regression was used to evaluate the association of statin, aspirin, other 
NSAIDs or chemotherapy use on pCR rate, rectal toxicity grade and time to maximum 
toxicity.  Actuarial analysis of time to maximum rectal toxicity was analysed using the 
Kaplan-Meier method and log-rank statistic.  Under the significance level of 0.05 and 
two-sided testing, p<0.05 is assumed to be statistically significant.  
 
 Results 
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Between 1
st
 September 2007 and 1
st
 June 2011, 142 patients were diagnosed with 
rectal cancer and received LCRT at RCTS.  Patient demographics of this group are 
outlined in Table 1.  Concurrent chemotherapy was given to 129 (91%) patients (106, 
16 and 7 with capecitabine, infusional and bolus 5FU respectively); 13 did not receive 
concurrent chemotherapy due to co-morbidities.   Eleven patients (7.7%) were 
known to have metastatic disease at the time of diagnosis, of which nine had 
concurrent chemo-RT.  Thirty three (23%) patients were taking a statin at the time of 
their LCRT (see Table 2), 28 using simvastatin and 5 using atorvastatin. Thirty-five 
(25%) patients were taking aspirin, 7 (5%) were taking other NSAIDs and 19 (13%) 
patients were taking both a statin and aspirin.  
 
After completion of LCRT, only 140 patients went on to surgery as 2 patients died 
prior to their surgical procedure.  In a further 5 patients the histological report was 
not obtainable and in all these cases their surgery was performed at a peripheral 
hospital.  Of the 135 assessable patients, 17 (13%) achieved a pCR at the time of 
surgery.  On logistic regression pCR was not significantly associated with the use of 
chemotherapy, statins, aspirin, other NSAIDs, T-stage or N-stage.   
 
Prospectively-recorded data was available on bladder and rectal toxicity during RT in 
141 patients.  The most severe toxicity recorded was grade 3 for both bladder and 
rectum, in 1 and 19 (13.5%) patients respectively.  Grade 1 and 2 bladder toxicities 
were recorded in 62 (44%) and 21 (14.9%) patients respectively, and grade 1 and 2 
rectal toxicities in 40 (28.4%) and 72 (51.1%) patients respectively (Table 2).  Of the 
129 patients who received concurrent chemotherapy, this treatment had to be 
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discontinued during RT in 47 (36%) due to toxicity and 15 patients (12%) were 
hospitalised for toxicity during treatment.  RT was stopped earlier than scheduled in 
7 patients (5%) due to toxicity. 
 
Univariate analysis was performed of correlations between the following 
parameters: age (as a continuous variable); tumour grade; T-, N- and M-stage; use of 
chemotherapy, statins, aspirin or other NSAIDs; time to, and maximum grade of 
bladder or rectal toxicity; early cessation of chemotherapy or RT; and pCR.  A 
significant correlation was seen between age and statin (r=0.19) or aspirin (r=0.29) 
use and an inverse correlation with chemotherapy use (r=-0.38) and N-stage (r=-
0.24; all p< 0.05).  Patients taking statins also had significantly lower N-stage (r=-
0.23) and those who received chemotherapy had significantly lower T-stage (r=-
0.21).  Grade of rectal toxicity was significantly associated with early cessation of 
chemotherapy (r=0.42).   
 
There was no significant correlation between statin or aspirin use with bladder or 
rectal toxicity (Figure 1).  Multinomial logistic regression was used to evaluate 
associations with grade of rectal toxicity: no interaction was seen with statin, aspirin 
or NSAID use, whereas chemotherapy was strongly associated with grade 3 toxicity 
(coefficient 15.3, p<0.00001). Actuarial time to maximum rectal toxicity was not 
different in statin users or non-users, when analysing either all patients (log-rank 
p=0.78) or those who had at least grade 2 toxicity (log-rank p= 0.44, Figure 2). 
 
Discussion 
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We undertook this retrospective study to specifically evaluate the effect of statins 
and aspirin on acute treatment toxicity and pCR rates in rectal cancer patients being 
treated with neo-adjuvant LCRT, with or without concurrent chemotherapy. This was 
inspired by reports from other groups, in larger datasets, that statins appeared to 
reduce the acute toxicity of treatment and increased the pCR rate (15-17;19), while 
statins and aspirin were each associated with improved overall colorectal cancer 
outcomes (3;22).  In this cohort of 142 patients, about a quarter of whom took either 
agent (13% took both), we were unable to demonstrate a significant benefit in either 
acute treatment-related toxicity or pCR rate from statin or aspirin use.  In contrast, 
adding chemotherapy to LCRT substantially increased the severity of toxicity, 
consistent with other reports (26), though in this series we did not see the improved 
histological outcome reported by others (27).   
 
While large population studies suggest that statins improve relapse and cancer-
specific survival in various cancers including rectal cancer (3;4;28-30), there appear 
to be beneficial interactions with RT that are not apparent with other treatments.  
Retrospective clinical studies report that patients taking statins during RT or chemo-
RT for rectal, bladder or prostate cancer had significantly higher rates of pathological 
complete response (pCR), local control and PSA progression-free survival, 
respectively (15-17;31-33).   In contrast no benefit from statin use was seen in a 
meta-analysis of surgical treatment of prostate cancer (31;33) nor adjuvant 
chemotherapy for colon cancer (18).  However, in a large breast cancer population 
the significantly-reduced relapse risk associated with statin use did not appear to 
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differ by specific cancer treatments, including RT, chemotherapy or endocrine 
therapy (29). 
 
Mechanisms that may contribute to improved cancer outcomes with statins relate 
either to direct effects on tumours (including generation of pro-apoptotic, growth-
inhibitory and pro-differentiation responses, radiosensitisation of tumour cells and 
inhibition of angiogenesis, invasion and metastasis) or to effects on normal tissues 
(reducing inflammation and inhibiting RT-induced intestinal and skin toxicities) (8-
13).  Statins can modify the acute RT-related normal tissue inflammatory response 
through inhibiting endothelial cell damage and activation, thus preventing 
recruitment of inflammatory cells into the tissues (11;12;34;35), with reduced late 
toxicities (and acute toxicities to a lesser extent) reported in preclinical models 
(12;13;36).  A solitary prospective observational study evaluating this in patients 
receiving radical pelvic RT showed statins significantly reduced RT-induced bowel 
toxicity, both during treatment and one year later (19). 
 
On the background of this significant body of preclinical and clinical work supporting 
potential clinically-significant benefits of statin use during RT, the lack of benefit in 
toxicity or pCR rate with statins found in this retrospective study is most likely due to 
its significant limitations. This single centre study has a small sample size and it was 
not possible retrospectively to collect data on ECOG performance status or other 
factors such as pre-treatment CEA levels which have been associated with higher 
odds ratios for pCR (17).  Similarly we were not able to evaluate a possible 
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interaction between dose or duration of aspirin or statin use, nor the late toxicity of 
treatment and disease outcome data.  We also acknowledge that the logistic 
regression analysis of the pCR rate and its association with other factors, including 
aspirin and statin use, will be limited by the small number of events (n = 17).  
 
Our results are also consistent with the possibility of there being no beneficial 
interaction of statins with RT in rectal cancer patients, or indeed for colon or rectal 
cancer overall, as reported by other authors (18;37).   Larger patient numbers than 
those we evaluated in this study are needed to discriminate the influence of statins 
and NSAIDS on treatment toxicities and outcomes separate to other prognostic 
variables. The true benefits of statins in this clinical setting can be best evaluated 
with the least bias and confounding by large, prospective, well-designed, 
randomised, placebo-controlled trials.  
 
Conclusion 
Although our study did not find improvements in toxicity or pCR rate through statin 
or aspirin use in rectal cancer patients undergoing LCRT, the preclinical and clinical 
data collectively present a compelling case for such trials to be conducted, especially 
in cancer patients who are being treated with RT.  Neo-adjuvant LCRT or chemo-RT 
in rectal cancer patients is a setting in which efficacy of statins in reducing toxicities 
can be combined with evaluating the histological, inflammatory and molecular 
effects of these agents in normal and malignant tissues.  The implications of such a 
benefit at a population level are profound, offering improved tolerability of RT and 
better cancer outcomes, using agents that have very low cost and toxicity.   
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Table 1: Patient Demographics 
 
Median age at diagnosis  69  (range 19 – 86)  
 
Gender 
 Male    106 (75%) 
 Female  36 (25%) 
 
Ethnicity 
 NZ European   99 (70%) 
 Maori    10 (7%) 
 Other European  18 (13%) 
 Not stated   15 (10%) 
 
 
TNM Stage 
 Stage I    4 (2.8%) 
 Stage II  35 (24.6%) 
 Stage III   92 (64.8%) 
 Stage IV   11 (7.7%) 
 
LCRT 
 With concurrent chemo 129 (91%)  
 Without chemo  13 (9%) 
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Table 2: Statin and aspirin use during neo-adjuvant long-course radiation 
treatment 
 
 On statins 
(n = 33) 
Not on 
statins 
(n = 109) 
On aspirin 
(n= 35) 
Not on 
aspirin† 
(n = 106) 
Gender 
         Male 
         Female 
 
25 (76%) 
8 (24%) 
 
81 (74%) 
28 (26%) 
 
29 (83%) 
6 (17%) 
 
76 (72%) 
30 (28%) 
Median age (range) 
71 
(59 – 84) 
67 
(19 – 86) 
72 
(54- 86) 
67 
(19 – 86) 
MRI Stage 
        Stage I 
        Stage II 
        Stage III 
        Stage IV 
 
2 (6.1%) 
14 (42.4%) 
16 (48.5%) 
1 (3%) 
 
2 (1.8%) 
21 (19.3%) 
76 (69.7%) 
10 (9.2%) 
 
1 (2.9%) 
12 (34.3%) 
20 (57.1%) 
2 (5.7%) 
 
3 (2.8%) 
23 (21.7%) 
71 (67%) 
9 (8.5%) 
Concurrent 
chemotherapy 
        Yes 
        No 
 
 
28 (85%) 
5 (15%) 
 
 
101 (93%) 
8 (7%) 
 
 
27 (77%) 
8 (23%) 
 
 
101 (95%) 
5 (5%) 
Maximal bladder 
toxicity 
        Grade 0 
        Grade 1 
        Grade 2 
        Grade 3 
        Unknown 
 
14 (42.4%) 
15 (45.5%) 
4 (12.1%) 
0 (0%) 
0 (0%) 
 
43 (39.4%) 
47 (43.1%) 
17 (15.6%) 
1 (0.9%) 
1 (0.9%) 
 
11 (31.4%) 
16 (45.7%) 
8 (22.9%) 
0 (0%) 
0 (0%) 
 
46 (43.4%) 
45 (42.5%) 
13 (12.3%) 
1 (0.9%) 
1 (0.9%) 
Maximal rectal 
toxicity 
        Grade 0 
        Grade 1 
        Grade 2 
        Grade 3 
        Unknown 
 
2 (6.1%) 
5 (15.1%) 
22 (66.7%) 
4 (12.1%) 
0 (0%) 
 
8 (7.3%) 
35 (32.1%) 
50 (45.9%) 
15 (13.8%) 
1 (0.9%) 
 
4 (11.4%) 
4 (11.4%) 
23 (65.7%) 
4 (11.4%) 
0 (0%) 
 
6 (5.7%) 
36 (34%) 
48 (45.3%) 
15 (14.2%) 
1 (0.9%) 
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Chemotherapy 
stopped due to 
toxicity 
        Yes 
        No 
        Not on chemo 
 
 
13 (39.4%) 
15 (45.5%) 
5 (15.1%) 
 
 
34 (31.2%) 
67 (61.5%) 
8 (7.3%) 
 
 
13 (37.1%) 
14 (40%) 
8 (22.9%) 
 
 
34 (32.1%) 
67 (63.2%) 
5 (4.7%) 
Radiation therapy 
stopped due to 
toxicity 
       Yes 
       No 
 
 
2 (6%) 
31 (94%) 
 
 
5 (5%) 
104 (95%) 
 
 
2 (6%) 
33 (94%) 
 
 
5 (5%) 
101 (95%) 
Pathological response 
Number assessable 
      Complete  
       Incomplete 
 
33 
3 (9.1%) 
30 (90.9%) 
 
102 
14 (13.7%) 
88 (86.3%) 
 
33
‡ 
6 (18.2%) 
27 (81.8%) 
 
101 
11 (10.9%) 
90 (89.1%) 
† In 1 paQent it was unknown if they were or were not taking aspirin 
‡ 1 paQent in the aspirin group died prior to surgery and 1 paQent had an unknown 
surgical histology 
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Figure Legends: 
Figure 1.  Distribution of maximum rectal toxicity grades during chemoradiation, 
according to statin use (Spearman R not significant). 
Figure 2.  Actuarial plot of time to maximum rectal toxicity in patients who had at 
least grade 2 toxicity. 
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Figure 1.  Distribution of maximum rectal toxicity grades during chemoradiation, according to statin use 
(Spearman R not significant).  
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Figure 2.  Actuarial plot of time to maximum rectal toxicity in patients who had at least grade 2 toxicity.  
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